Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production
Biomolecules · 2025
DOI: 10.3390/biom15081166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Viktoriya Keyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Biotechnology, Korgalzhin hwy 13/5, Astana 010000, Kazakhstan. Hauptthemen laut MEDLINE: Lentivirus, Immunotherapy, Adoptive, Genetic Vectors, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.
Abstract (Originalsprache)
CAR-T cell therapy represents a breakthrough in cancer treatment, yet its implementation in developing countries remains challenging due to technical and infrastructural barriers. This study aimed to establish clinical-scale CAR-T production in Kazakhstan, a country with no prior experience in advanced cell and gene therapies. We implemented a complete CAR-T manufacturing pipeline, including in-house lentiviral vector (LV) production and automated CAR-T cell processing using the CliniMACS Prodigy system. Two anti-CD19 CAR LVs were used, one modeled after FDA-approved Kymriah (4-1BB costimulation) and another replicating Yescarta (CD28 costimulation). The vector produced locally achieved functional titers of 1.5 × 1010 TU/mL after concentration. Twelve clinical-scale CAR-T products were manufactured, exhibiting a memory-skewed T-cell phenotype. Functional assessments revealed that CD28-based CAR-T cells produced significantly higher Th1 cytokines (IFN-γ, TNF-α, IL-2; p < 0.05) than 4-1BB-based cells, though both demonstrated comparable cytotoxicity against CD19+ targets. These findings demonstrate the feasibility of establishing CAR-T production in resource-limited settings using a decentralized manufacturing framework. This work provides a scalable model of CAR-T therapy production in developing regions, suitable for clinical implementation using the hospital exemption framework. Critical gaps in access to advanced immunotherapies, including CAR-T, in the Central Eurasia region are addressed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Biotechnology, Korgalzhin hwy 13/5, Astana 010000, Kazakhstan.
- Scientific-Production Center of Transfusiology, Zhanibek Khandar St., 10, Astana 010000, Kazakhstan.
ORCID-Profile: Viktoriya Keyer, Gulzat Zauatbayeva, Dmitrii Bazhenov, Alexandr V Shustov
Förderung
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Zitieren
APA
Keyer, V., Kydyrbayeva, A., Kulatay, T., Zauatbayeva, G., Bazhenov, D., Ingirbay, B., Shakhmanova, Z., Zhumabekova, M., Ospanova, M., & Shustov, A. V. (2025). Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production. Biomolecules. https://doi.org/10.3390/biom15081166
Vancouver
Keyer V, Kydyrbayeva A, Kulatay T, Zauatbayeva G, Bazhenov D, Ingirbay B, et al. Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production. Biomolecules. 2025. doi:10.3390/biom15081166
BibTeX
@article{Keyer2025,
author = {Keyer, Viktoriya and Kydyrbayeva, Aitolkyn and Kulatay, Tolganay and Zauatbayeva, Gulzat and Bazhenov, Dmitrii and Ingirbay, Bakytkali and Shakhmanova, Zhanar and Zhumabekova, Maral and Ospanova, Madina and Shustov, Alexandr V},
title = {Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15081166}
}
EUVIMED